Hepatic preconditioning of doxorubicin in stop-flow chemotherapy: NF-&kappa;B/I&kappa;B-&alpha; pathway and expression of HSP72

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 14

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

262

HTML

2041

Figures (1-4)

172

Sum=2475

Apr 14, 2005 (publication date) through Apr 30, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Apr 14, 2005; 11(14): 2136-2141
Published online Apr 14, 2005. doi: 10.3748/wjg.v11.i14.2136

Full Size Figure Download Figure

Figure 1 Western blot analysis of HSP72 (A) and NF-κB p65 subunit (B) in liver cytoplasmic extracts before SFC in NS and DOX groups.

Citation: Lu H, Zhu ZG, Yao XX, Zhao R, Yan C, Zhang Y, Liu BY, Yin HR, Lin YZ. Hepatic preconditioning of doxorubicin in stop-flow chemotherapy: NF-κB/IκB-α pathway and expression of HSP72. World J Gastroenterol 2005; 11(14): 2136-2141
URL: https://www.wjgnet.com/1007-9327/full/v11/i14/2136.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i14.2136